08/09/2026 Vor Bio announced the completion of enrollment in its Phase 3 trial of telitacept in gMG Spyre Therapeutics announced Phase 2 Part A induction results for SPY003 in UC Alebund Pharmaceuticals announced FDA clearance of its IND application for AP308 for the treatment of IgA Nephropathy Greywolf Therapeutics dosed the first participant with axSpA in the Ph1/2 trial of GRWD0715. Vor Bio announced the completion of enrollment in its Phase 3 trial of telitacept in gMG.

25/08/2026 Spyre Therapeutics announced topline results from the RA Sub-study of the Phase 2 SKYWAY trial of SPY072 Spyre Therapeutics announced topline results from the RA Sub-study of the Phase 2 SKYWAY trial of SPY072 (Ref) Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2, SKYWAY-RD/ NCT07148414 basket trial evaluating SPY072 (Anti-TL1A) in rheumatic diseases. Both the doses of SPY072 demonstrated statistically signif

03/06/2026 Johnson & Johnson late-breaking results showed nipocalimab significantly reduced SLE disease activity in a Phase 2 study Johnson & Johnson announced biomarker exploratory analyses from a Phase 2 study of nipocalimab in moderate-to-severe SjD Argenx presented efgartigimod data showing long-term sustained patient benefit in myositis and SjD at EULAR-2026 JJP Biologics announces positive interim Phase 1b data for nebaprubart in Linear IgA Disease Spyre Therapeutics an